Biotech Business › Vol. 19 Nbr. 5, May 2006
Linked as:Extract
ORPHAN THERAPEUTICS COMPLETES ENROLLMENT FOR TERLIPRESSIN.
PDL BioPharma, Inc. (PDL) (NASDAQ:PDLI), Fremont, Calif.,has announced that its partner, Orphan Therapeutics LLC, has completed enrollment in the pivotal Phase 3 clinical research study of terlipressin for the treatment of type 1 ...
See the full content of this document
Sponsored links
ver las páginas en versión mobile | web
ver las páginas en versión mobile | web
© Copyright 2012, vLex. All Rights Reserved.
Contents in vLex United States
Explore vLex
For Professionals
For Partners
Company
Other documents:
Moore v. The State., 181 Ga. App. 548, 352 S.E.2d 821 (1987) | 29 CFR 531.35 “Free and clear” payment “kickbacks.” | 28 CFR 51.4 Date used to determine coverage list of covered jurisdictions. | us v. almon, (4th cir. 2004) | Sentencia nº 4331 de Consiglio di Stato July 29 2008 | sentenza breve nº 2760 de consiglio di stato, may 15, 2012 | SVS rechaza apelación de CB Corredores de Bolsa | Continúa la protesta
